The bacteria that cause the extremely contagious disease strangles, sometimes referred to as "distemper," is called Streptococcus equi, or S. equi. When S. equi infections occur, there is a significant inflammatory reaction. Fever, dysphagia or anorexia, stridor, lymphadenopathy, and abundant mucopurulent nasal discharge are examples of clinical symptoms.
Clinical signs may include fever, dysphagia or anorexia, stridor, lymphadenopathy; and copious mucopurulent nasal discharge. Although strangles usually affect young horses (weanlings and yearlings), horses of any age can be infected. S. equi can be transmitted through direct contact with infected horses or sub-clinical shedders, but also through indirect contact with water troughs, hoses, or attendants’ hands and clothing.
Vaccination against S. equi is suggested on premises where strangles are persistent endemic problems or for horses that are expected to be at high risk of exposure. There are several vaccines available for S. equi, including recombinant subunit vaccines.
Strangvac, Recombinant S. equi Vaccine
Strangvac is a multi-component chimeric fusion protein vaccine used to prevent S. equi. The active ingredients of Strangvac are derived from CNE, SclC, SclF, SclI, and EAG (fused as CCE), SEQ_0402 and SEQ_0256 (fused as Eq85), and IdeE produced in Escherichia coli (E. coli). Strangvac uses purified quillaia saponin QS-21 (Fraction C) as an adjuvant.
Strangvac was developed by Intervacc and obtained a marketing authorization valid from EMA in August 2021.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Vaccines
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
